Michael Loberg
Keine laufenden Positionen mehr
Vermögen: 634 399 $ am 30.04.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Felix Baker | M | 55 | 3 Jahre | |
| M. Wilsey | M | 71 | 5 Jahre | |
| Michael Lee | M | 45 | 5 Jahre | |
| Julie Hambleton | M | 66 | 6 Jahre | |
| Jakob Haldor Topsøe | M | 55 | 6 Jahre | |
| Christina Teng Topsøe | F | 43 | 6 Jahre | |
| William Strohl | M | 71 | 6 Jahre | |
| T. S. Harigopal | M | - | 3 Jahre | |
| Sandra Leung | F | 63 | 32 Jahre | |
| Paul Graffagnino | M | - | 3 Jahre | |
| Angus M. Sinclair | M | - | 6 Jahre | |
| George Gauthier | M | 52 | 3 Jahre | |
| Steven Weber | M | 48 | 2 Jahre | |
| Chris Takimoto | M | 65 | 3 Jahre | |
| Suzette Tauber | F | - | 5 Jahre | |
| Misbah Tahir | M | 49 | 5 Jahre | |
| Lisa Decker | M | 55 | 3 Jahre | |
| John Shiver | M | 66 | 3 Jahre | |
| James Milke | M | - |
University of Maryland
| 47 Jahre |
| Lisa Wax | F | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Jerome Goldstein | M | 84 | 26 Jahre | |
| James G. Ham | M | 74 |
Inotek Pharmaceuticals Corp.
 Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA.
NitroMed, Inc.
 NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | 17 Jahre |
| Ken Bate | M | 73 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | 3 Jahre |
| Argeris Karabelas | M | 71 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA.
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 12 Jahre |
| Davey Scoon | M | 78 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA.
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 17 Jahre |
| Peter R. Dolan | M | 68 | 18 Jahre | |
| Yim-Pan Cheung | M | 77 |
University of Maryland
| 10 Jahre |
| Charles A. Heimbold | M | - | 20 Jahre | |
| Paul Howes | M | 69 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | - |
| Joseph Farmer | M | 52 | - | |
| Michael Narachi | M | 64 | 8 Jahre | |
| Paolo Pucci | M | 63 | - | |
| John E. Celentano | M | 64 | 31 Jahre | |
| Robert Weiskopf | M | 73 | 12 Jahre | |
| Brian Pereira | M | 65 | 7 Jahre | |
| Stephen Hill | M | 65 | 9 Jahre | |
| David Southwell | M | 63 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 Jahre |
| William McVicar | M | 66 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 10 Jahre |
| Aris Mardirossian | M | - |
University of Maryland
| 5 Jahre |
| Robert Wasilewski | M | - |
University of Maryland
| 4 Jahre |
| Joseph Vincent Bonventre | M | 74 | 5 Jahre | |
| Shmuel Peleg | M | - |
University of Maryland
| 3 Jahre |
| Ittai Harel | M | 56 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 6 Jahre |
| Frank M. Deane | M | 74 |
University of Maryland
| 3 Jahre |
| David G. Bostwick | M | 69 |
University of Maryland
| 8 Jahre |
| Elizabeth S. Baker | F | - |
University of Maryland
| 3 Jahre |
| Andrew Charles Palmer | M | - |
University of Maryland
| 7 Jahre |
| Burton J. Haynes | M | 76 |
University of Maryland
| 6 Jahre |
| Marc Schegerin | M | 48 | 2 Jahre | |
| Dawn Schottlandt | F | - | 3 Jahre | |
| Parvinder S. Hyare | M | - | - | |
| Neville Joseph Chang | M | - |
University of Maryland
| 6 Jahre |
| Howard K. Kurman | M | - |
University of Maryland
| 7 Jahre |
| Isai Peimer | M | 46 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 3 Jahre |
| Chris Bliss | M | - |
University of Maryland
| 6 Jahre |
| William J. Schroeder | M | - |
University of Maryland
| 4 Jahre |
| Susan Kelley | M | 69 | 9 Jahre | |
| Michael Dalpee | M | - |
University of Maryland
| 6 Jahre |
| Charles Bancroft | M | 65 | 36 Jahre | |
| Gary L. Hall | M | 70 |
University of Maryland
| 7 Jahre |
| Rosemary Crane | F | 64 | 20 Jahre | |
| Bill Wainger | M | - |
University of Maryland
| 4 Jahre |
| Emma Reeve | F | 63 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 10 Jahre |
| Joseph Squicciarino | M | 67 | 22 Jahre | |
| Mark W. Durand | M | 64 | 17 Jahre | |
| Timothy G. Healey | M | 58 | - | |
| Ron Zwanziger | M | 70 | 5 Jahre | |
| Hal Sternberg | M | 70 |
University of Maryland
| 7 Jahre |
| Steven B. Ratoff | M | 81 | 16 Jahre | |
| Christina McMullen | F | 68 |
University of Maryland
| 7 Jahre |
| Harrison Bains | M | 80 | 16 Jahre | |
| Charles Sigal | M | 72 | 16 Jahre | |
| Robert Perez | M | 59 | 11 Jahre | |
| Anthony Hooper | M | 69 | 15 Jahre | |
| Lawrence Hamilton | M | 66 | 8 Jahre | |
| Timothy Meeker | M | 77 | 13 Jahre | |
| Edward C. English | M | 57 | 4 Jahre | |
| Richard H. Woodrich | M | 78 | 1 Jahre | |
| William Jones | M | 60 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | 15 Jahre |
| Béatrice J. Cazala | F | 67 | 32 Jahre | |
| James Robinson | M | 88 | 29 Jahre | |
| Priya Jambhekar | F | - | 3 Jahre | |
| Jane A. Kramer | F | 68 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | 15 Jahre |
| Zola P. Horovitz | M | 89 |
NitroMed, Inc.
NitroMed, Inc. Pharmaceuticals: MajorHealth Technology NitroMed, Inc. develops and supplies pharmaceuticals. It offers BiDil, an orally administered medicine for the treatment of heart failure. The firm also develops products for cardiovascular and metabolic diseases. The company was founded in 1987 and is headquartered in Atlanta, GA. | 12 Jahre |
| Robert J. Massey | M | 78 | - | |
| Devang Vallabhdas Kantesaria | M | 51 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 4 Jahre |
| Susan M. O'Toole | F | 74 | - | |
| Thomas V. Costantino | M | - |
University of Maryland
| 5 Jahre |
| Steve J. Andriole | M | - |
University of Maryland
| 3 Jahre |
| Martin Vogelbaum | M | 60 |
Inotek Pharmaceuticals Corp.
Inotek Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Inotek Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. The company's product candidate includes Trabodenoson, an adenosine mimetic that has completed Phase II clinical trials for lowering IOP by restoring the eye's natural pressure control mechanism. It is also developing Trabodenoson plus Latanoprost, a prostaglandin analogue that has completed Phase II clinical trials for use in patients with inadequate responses to treatment with latanoprost; and Trabodenoson monotherapy for the treatment of optic nerve neuropathy. Inotek Pharmaceuticals was founded on July 7, 1999 by Csaba Szabo and Andrew L. Salzman and is headquartered in Lexington, MA. | 6 Jahre |
| Laurie Glimcher | M | 72 | 20 Jahre | |
| N. Coles | M | 63 | - | |
| Ellen H. Yankellow | M | - |
University of Maryland
| 4 Jahre |
| Omar Sjawaldy Anwar | M | 64 |
University of Maryland
| 4 Jahre |
| John Yokley | M | - |
University of Maryland
| 4 Jahre |
| Beverly Eichel | F | 66 |
University of Maryland
| 4 Jahre |
| Ning Yan | M | - | 7 Jahre | |
| Andrew Sherman | M | - |
University of Maryland
| 4 Jahre |
| Elliot Bart Stiefel | M | - |
University of Maryland
| 4 Jahre |
| Nina C. Millman | F | - |
University of Maryland
| 4 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Michael Loberg
- Persönliches Netzwerk
